Showing 2241-2250 of 2657 results for "".
- GlobalData: Glaucoma Market to Grow to $3.5 Billion by 2030, Driven by Launch of New Pipeline Productshttps://modernod.com/news/globaldata-glaucoma-market-to-grow-to-35-billion-by-2030-driven-by-launch-of-new-pipeline-products/2480609/Steady growth is expected for the glaucoma market across the seven major markets* from $2.8 billion in 2020 to $3.5 billion in 2030, at a compound annual growth rate (CAGR) of 2.0%, according to GlobalData. According to the leading data and analytics company’s latest re
- FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Wet AMD and DMEhttps://modernod.com/news/fda-approves-genentechs-vabysmo-the-first-bispecific-antibody-for-the-eye-to-treat-wet-amd-and-dme/2480603/The FDA has approved Genentech's Vabysmo (faricimab-svoa) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME), marking the first bispecific antibody approved for the eye. Vabysmo is also the first and only FDA-approved inj
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officerhttps://modernod.com/news/foundation-fighting-blindness-promotes-jason-menzo-to-president-and-chief-operating-officer/2480580/The Foundation Fighting Blindness announced the promotion of Jason Menzo to president and chief operating officer, effective immediately. Since joining the Foundation in 2018, Mr. Menzo has had a profound positive impact on redefining the non-profit’s operations, includi
- Avellino Enters Into Distribution Agreement With Keeler to Sell Genetic Eye Test AvaGenhttps://modernod.com/news/avellino-enters-into-distribution-agreement-with-keeler-to-sell-genetic-eye-test-avagen/2480576/Avellino Lab USA and Keeler have entered into an agreement where Keeler will distribute AvaGen on its US website. Terms of the deal were not disclosed. AvaGen is the first genetic test that helps determine a patient’s risk of keratoconus and the presence
- Seoul Semiconductor Proves the Effect of SunLike Lighting on Myopia Improvementhttps://modernod.com/news/seoul-semiconductor-proves-the-effect-of-sunlike-lighting-on-myopia-improvement/2480573/Seoul Semiconductor announced that it has confirmed SunLike lighting’s effect on improving myopia, along with SERI_Singapore Eye Research Institute. In order to prove the correlation between health and SunLike, a natural lighting technology developed through years of R&D,
- Modular Super-Enhancer Controls Retinal Developmenthttps://modernod.com/news/modular-super-enhancer-controls-retinal-development/2480571/Scientists at St. Jude Children’s Research Hospital identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer. Enhancers are regions of DNA that do not
- Bausch + Lomb Files Registration Statement for Proposed Initial Public Offeringhttps://modernod.com/news/bausch-lomb-corporation-files-registration-statement-and-preliminary-prospectus-for-proposed-initial-public-offering/2480570/Bausch Health Companies announced that in connection with its previously announced intention to separate its eye health business, its wholly owned subsidiary, Bausch + Lomb, has publicly filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SE
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division with Acquisition of Warden Biohttps://modernod.com/news/kriya-expands-gene-therapy-pipeline-and-establishes-its-rare-disease-therapeutic-area-division-with-the-acquisition-of-warden-bio/2480550/Gene therapy company Kriya Therapeutics announced that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs). Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs.</